ZYPREXA Drug Patent Profile

Which patents cover Zyprexa, and what generic alternatives are available?

Zyprexa is a drug marketed by Cheplapharm and is included in four NDAs.

The generic ingredient in ZYPREXA is olanzapine pamoate. There are thirty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olanzapine pamoate profile page.

Summary for ZYPREXA

US Patents:	0
Applicants:	1
NDAs:	4
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	119
Clinical Trials:	132
Patent Applications:	4,890
Drug Prices:	Drug price information for ZYPREXA
What excipients (inactive ingredients) are in ZYPREXA?	ZYPREXA excipients list
DailyMed Link:	ZYPREXA at DailyMed

See drug prices for ZYPREXA

See drug sales revenues for ZYPREXA

Recent Clinical Trials for ZYPREXA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Teva Branded Pharmaceutical Products R&D, Inc.	PHASE1
Teva Branded Pharmaceutical Products R&D LLC	PHASE1
OHSU Knight Cancer Institute	Phase 2

See all ZYPREXA clinical trials

Pharmacology for ZYPREXA

Drug Class

Atypical Antipsychotic

US Patents and Regulatory Information for ZYPREXA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cheplapharm	ZYPREXA	olanzapine	POWDER;INTRAMUSCULAR	021253-001	Mar 29, 2004	AP	RX	Yes	Yes
Cheplapharm	ZYPREXA	olanzapine	TABLET;ORAL	020592-006	Sep 9, 1997	AB	RX	Yes	No
Cheplapharm	ZYPREXA	olanzapine	TABLET;ORAL	020592-003	Sep 30, 1996	AB	RX	Yes	No
Cheplapharm	ZYPREXA ZYDIS	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	021086-002	Apr 6, 2000	AB	RX	Yes	No
Cheplapharm	ZYPREXA RELPREVV	olanzapine pamoate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022173-001	Dec 11, 2009		RX	Yes	No
Cheplapharm	ZYPREXA ZYDIS	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	021086-004	Apr 6, 2000	AB	RX	Yes	No
Cheplapharm	ZYPREXA	olanzapine	TABLET;ORAL	020592-001	Sep 30, 1996	AB	RX	Yes	No

Expired US Patents for ZYPREXA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cheplapharm	ZYPREXA	olanzapine	TABLET;ORAL	020592-004	Sep 30, 1996
Cheplapharm	ZYPREXA	olanzapine	TABLET;ORAL	020592-006	Sep 9, 1997
Cheplapharm	ZYPREXA	olanzapine	TABLET;ORAL	020592-001	Sep 30, 1996
Cheplapharm	ZYPREXA	olanzapine	TABLET;ORAL	020592-003	Sep 30, 1996
Cheplapharm	ZYPREXA	olanzapine	TABLET;ORAL	020592-005	Sep 9, 1997
Cheplapharm	ZYPREXA	olanzapine	TABLET;ORAL	020592-002	Sep 30, 1996

EU/EMA Drug Approvals for ZYPREXA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Zyprexa Velotab	olanzapine	EMEA/H/C/000287AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	no	no	no	2000-02-03
Eli Lilly Nederland B.V.	Zypadhera	olanzapine	EMEA/H/C/000890Maintenance treatment of adult patients with schizophrenia sufficiently stabilised during acute treatment with oral olanzapine.	Authorised	no	no	no	2008-11-19
Eli Lilly Nederland B.V.	Zyprexa	olanzapine	EMEA/H/C/000115Coated tabletsAdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.InjectionAdultsZyprexa powder for solution for injection is indicated for the rapid control of agitation and disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate. Treatment with Zyprexa powder for solution for injection should be discontinued and the use of oral olanzapine should be initiated as soon as clinically appropriate.	Authorised	no	no	no	1996-09-27
Krka	Zalasta	olanzapine	EMEA/H/C/000792Olanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	yes	no	no	2007-09-27
Mylan Pharmaceuticals Limited	Olanzapine Mylan	olanzapine	EMEA/H/C/000961AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	yes	no	no	2008-10-06
Teva B.V.	Olanzapine Teva	olanzapine	EMEA/H/C/000810AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	yes	no	no	2007-12-12
Apotex Europe BV	Olanzapine Apotex	olanzapine	EMEA/H/C/001178Olanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	yes	no	no	2010-06-10

International Patents for ZYPREXA

See the table below for patents covering ZYPREXA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	127804
Australia	643267
Australia	7518691
Bulgaria	61710
Canada	2041113	DERIVES DE LA THIENOBENZODIAZEPINE ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES (THIENOBENZODIAZEPINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS)
China	1028429
China	1056693

Supplementary Protection Certificates for ZYPREXA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0454436	CA 2001 00042	Denmark
0454436	C970015	Netherlands		PRODUCT NAME: OLANZAPINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927
0454436	SPC/GB96/058	United Kingdom		PRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927
0454436	97C0012	Belgium		PRODUCT NAME: OLANZAPINE; REGISTRATION NO/DATE: EU/1/96/022/001 19960927
0454436	9/1997	Austria		PRODUCT NAME: OLANZAPIN ODER EIN SAEUREADDITIONSSALZ HIEVON; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927

Last updated: June 24, 2026

Zyprexa (olanzapine) market dynamics and financial trajectory: revenue drivers, patent cliff risk, and generic/biosimilar outlook

Zyprexa (olanzapine) has transitioned from a protected brand into a genericized antipsychotic market, with revenue now dominated by (1) remaining branded access where formularies restrict substitution and (2) generic volume and pricing. The market’s financial trajectory is shaped by patent and exclusivity run-off, post-generic price compression, and competitive substitution inside second-generation antipsychotics (SGAs), especially risperidone, quetiapine, aripiprazole, and paliperidone.

---

What drove Zyprexa sales growth and market share versus competing SGAs?

Core commercial rationale. Zyprexa is an oral and long-acting antipsychotic used across schizophrenia and bipolar indications. Its historical market share gains came from efficacy perceived by prescribers, broad prescriber adoption, and an expanding claims footprint into bipolar maintenance and related uses.

Key market dynamics by era (high level).

• Launch and adoption phase: Brand marketing and clinician familiarity supported uptake against first-generation antipsychotics and earlier SGAs.
• Peak brand phase: Competitive pressure emerged as newer SGAs gained formulary preference, but Zyprexa retained share due to perceived efficacy breadth.
• Post-patent phase: Generic entry drove steep net price erosion, pushing revenue toward unit volumes and payor contracting.
• Ongoing share contest: Market share shifted toward payor-preferred SGAs when generics or lower-cost brands entered, reducing Zyprexa’s ability to hold premium pricing.

Competition that structurally compresses pricing.

• Risperidone (including long-acting formulations) with wide generic availability.
• Quetiapine and aripiprazole (and long-acting forms), often used as formulary alternatives with favorable cost-per-treated member.
• Paliperidone with strong differentiation in schizoaffective and schizophrenia lines in some systems.

Financial implication. Even if Zyprexa maintains prescriber familiarity, SGAs are typically substitutable at the plan level. That substitution plus generic erosion is the dominant driver of brand revenue decline post-exclusivity.

---

When did Zyprexa lose exclusivity and what does that mean for revenue and pricing?

Exclusivity outcome. Zyprexa’s major revenue trajectory is tied to the end of patent-protected brand competition in the US. Once generics entered, the remaining market for the brand became mostly “switch resistant” for specific patients and constrained formularies.

Commercial effects of genericization.

• Brand revenue falls toward low-single-digit market share as formularies and PBMs favor generics.
• Net price drops sharply even when a brand remains on formularies, because rebates and positioning have to justify higher acquisition cost.
• Volume share can persist in certain settings, but revenue is still dominated by lower-priced competitors.

Investor lens. For antipsychotics, the patent cliff typically produces a “step down” in brand revenue followed by a prolonged period of depressed unit profitability. The slope depends on:

• timing of generic entry for each dosage form and indication,
• whether long-acting formulations have separate patent or data protection,
• PBM contracting intensity and therapeutic interchange policies.

---

What patents protect Zyprexa and how does the patent estate affect generic entry risk?

Zyprexa is built on olanzapine composition, use, and pharmaceutical formulation claims across jurisdictions. Generic entry generally tracks when legally defensible barriers clear, including:

• expiration of composition-of-matter patents,
• expiration or invalidation of method-of-use patents,
• formulation patent expiration or carveouts for specific dosage forms.

Practical patent estate effect. Once the core composition and key use patents expire, generics can enter with an ANDA, and revenue is rapidly competed down via pricing. Secondary barriers (formulation and method-of-use) matter mainly if they delay filing or create switching restrictions in labeling.

Long-acting products. Any long-acting or specialty delivery platform for olanzapine (if present for a given market) can have additional claim sets that extend contestation relative to immediate-release tablets.

---

What is the Orange Book status of Zyprexa in the US?

Zyprexa’s US status on the FDA Orange Book is the operational map for generic launch timing. Orange Book listings typically include:

• active ingredient coverage,
• formulation or method-of-use patents,
• listed expiration dates and exclusivity codes tied to the NDA history.

Orange Book status determines whether ANDA filers can cite patents via Paragraph IV (if patents are claimed but believed invalid/not infringed) or must wait for expiration.

---

How many ANDA filings and Paragraph IV challenges occurred for Zyprexa?

For Zyprexa, the post-brand era is characterized by the inevitability of ANDA competition once the primary patent barriers cleared. The commercial pattern in this category is:

• multiple ANDAs around the generic “unlock” date for each dosage form,
• early Paragraph IV strategies where filers believe patents are weak or design-around is feasible,
• litigation that can delay entry by a limited window even when ultimate outcome favors generics.

Financial consequence. The first wave of ANDAs typically produces the largest net price erosion for the brand. Later filings tend to play out as incremental volume share shifts at lower pricing.

---

What patent litigation affected Zyprexa generic entry timelines?

Patent litigation in the US for small molecules often influences:

• the entry date for first generic filers,
• whether the brand maintains a temporary injunction or receives a delayed settlement trigger,
• the sequencing of later entrants.

Commercial impact model.

• A successful brand motion can delay first generic entry and delay price compression.
• A settlement with delayed launch can create a temporary “bridge” that preserves brand revenue.
• If patents are invalidated or non-infringement is found early, price compression starts sooner and faster.

---

Did any Zyprexa settlement agreements delay generic entry?

In the class of blockbuster oral small-molecule brands, settlements often take the form of delayed launch dates or exclusivity arrangements. For Zyprexa, the settlement effect would be visible in:

• delayed earliest generic approval date relative to patent expiration,
• differences in entry timing across dosage strengths or manufacturers.

Financial trajectory implication. Settlements can alter the timing of the steepest revenue drop, but they do not usually prevent long-term generic price erosion once primary patents expire.

---

What formulations of Zyprexa were most commercially material, and how does that affect revenue?

Zyprexa’s revenue history depends on which dosage forms remain commercially active post-genericization:

• Immediate-release oral formulations (tablets and orally disintegrating variants, where applicable).
• Any long-acting olanzapine formulation, if commercially marketed under the Zyprexa name in the relevant market.

Revenue logic.

• Immediate-release generics typically compete most aggressively because manufacturing is less complex.
• Specialty formulations and any long-acting systems can reduce the speed of switching because of administration training, budget impact, and contracting preference.

---

How did Zyprexa revenues trend after generic launches in the US?

Typical post-generic pattern for SGAs.

• Brand revenue decreases sharply after first generic entry, driven by formulary switching and PBM contracting.
• Net revenue becomes less correlated with market incidence and more correlated with plan-level access and rebate competitiveness.
• Unit volume can stay steady or decline modestly, but revenue trends down due to lower net prices and higher competition.

What this means for a financial trajectory assessment.

• If you model Zyprexa as a mature small molecule SGA, the forecast is dominated by pricing compression rather than volume loss alone.
• The “shape” of the decline is steeper at first entry and flattens as the market matures with multiple interchangeable generics.

---

How does Zyprexa compare financially with other major SGAs (risperidone, quetiapine, aripiprazole) after exclusivity?

Relative drivers of post-cliff performance.

• Risperidone and quetiapine often retain stronger baseline formularies due to extensive generic ecosystems and mature prescriber comfort.
• Aripiprazole can retain share through both oral and long-acting options, depending on plan preference and patient suitability.
• Zyprexa faces specific clinical substitution resistance because of patient tolerability profiles and clinician experience, but cost pressures still drive generic uptake.

Commercial outcome. After exclusivity ends, antipsychotic brands generally converge toward low-net-price economics. Zyprexa’s differentiation tends to be clinically driven rather than patent-driven, so it usually cannot outgrow pricing compression once generics become the default.

---

What is the biosimilar risk for Zyprexa?

Zyprexa is a small-molecule drug (olanzapine). Biosimilar risk is not applicable because biosimilars are relevant to biologics. Competition risk comes from generics and authorized generics, not biosimilar substitution.

---

What generic entry risks exist for Zyprexa across global markets?

Global trajectory depends on:

• national patent status and enforcement,
• regulatory approval pathways for generics,
• local formulary and PBM practice,
• manufacturing competition and price ceilings.

Typical international pattern.

• once core patents expire, generic launches accelerate,
• the largest revenue impact usually follows US and EU patent cliffs earliest,
• subsequent market growth is usually driven by incidence and dose utilization, not brand pricing.

---

What regulatory pathway governs generic competition for Zyprexa?

In the US, generics compete via the ANDA route, with:

• bioequivalence requirements to the reference listed drug,
• patent certifications tied to Orange Book listings (Paragraph I-IV),
• litigation and settlement-driven entry timing for Paragraph IV scenarios.

Commercial outcome. Regulatory approval is usually not the bottleneck after patents clear. Contracting and substitution are the primary commercial drivers.

---

What manufacturing or IP barriers can still protect Zyprexa branded share post-patent?

Post-patent barriers typically do not block generics on legal grounds, but they can reduce how quickly branded prescriptions convert:

• formulary restrictions (prior authorization requirements),
• therapeutic substitution rules (plan-specific),
• patient-specific tolerability (clinician reluctance to switch),
• supply and contract terms with PBMs.

This is not patent protection, but it can delay conversion in practice and sustain low-level branded revenue.

---

Key timeline: exclusivity run-off, generic entry, and market pricing effects

Because Zyprexa is already in a post-blockbuster era, the commercially relevant timeline is the “generic unlock” window rather than ongoing exclusivity:

Timeline framework used in antipsychotics market modeling

1. Last meaningful patent expiration date (primary composition or key use).
2. Earliest ANDA approval date for first generic wave.
3. Second wave of approvals that expand the number of competitors and intensify price pressure.
4. Long-term stabilization where multiple generics reduce the brand to a low-access niche.

The financial trajectory follows this structure: brand revenue peaks prior to step (2), drops sharply at step (2), and continues a downward slope with each expanding competitor set.

---

Where does Zyprexa stand in 2026: competitive landscape and commercial positioning?

Market character. The competitive landscape is dominated by low-cost generics and plan-level contracting. In this environment:

• the brand’s revenue base is mostly access-driven rather than monopoly-driven,
• the business case for additional brand investment is usually weak,
• the market is still commercially active because schizophrenia and bipolar disorder prevalence maintains ongoing demand.

What to watch next for market dynamics

• consolidation among generic manufacturers can temporarily reduce price competition or improve supply reliability,
• PBM formulary updates can cause episodic switches,
• any remaining non-expired patents or delayed claim clearances can create limited pockets of exclusivity for specific strengths or formulations.

---

Key Takeaways

• Zyprexa’s financial trajectory is primarily a post-exclusivity story: once core patents cleared, generic entry drove sustained net price erosion and reduced branded revenue to low-access niches.
• Competitive dynamics are structural for SGAs: payors and PBMs favor interchangeable alternatives, so branded premium pricing is hard to defend after genericization.
• Patent litigation and settlements can shift the timing of entry, but they rarely prevent long-term pricing compression once key barriers expire.
• Biosimilar risk does not apply because Zyprexa is a small molecule.

---

FAQs

1) What happens to Zyprexa revenue immediately after first generic approval?
The steepest decline typically occurs with the first wave of ANDA launches because formulary switching and PBM contracting accelerate net price compression.

2) Which Zyprexa strengths tend to see faster erosion?
Formulations with the most manufacturing simplicity and quickest ANDA scalability usually see faster price drops, especially immediate-release products.

3) Can prior authorization preserve Zyprexa branded use after generics launch?
Yes, at the margin. Prior authorization and step-therapy can slow switching for specific patients, sustaining limited branded access.

4) How do Zyprexa losses compare with other SGAs after exclusivity?
All mature SGAs face similar “generic pricing convergence,” but the speed depends on the breadth of generic entry and plan-level interchange practices.

5) What is the main driver of future unit demand for Zyprexa?
Disease prevalence and dosing patterns, not patent protection. Commercial economics are then determined mainly by pricing and contracting.

---

References (APA)

No sources were provided in the prompt, and no external Orange Book, FDA, or litigation dataset was supplied for this specific analysis.

DrugChatter Q&A for ZYPREXA

Zyprexa zydis discount card?
How much does zyprexa cost?
Generic zyprexa vs brand name?
Zyprexa cost without insurance?
Zyprexa generic olanzapine patent?